ACADEMIA

Avigan Fails to Hit Statistical Significance in COVID-19 Trial: Fujita Health Univ.

July 13, 2020
Patients who received early treatment with Fujifilm’s antiviral agent Avigan (favipiravir) tended to show better recovery than those who did not, but not by a statistically significant margin, according to the results of an investigator-led study released on July 10.…

To read the full story

Related Article

ACADEMIA

By Yoshinori Sagehashi

Discussions are underway in and outside the pharmaceutical industry to explore a new NHI price revision method for listed medicines that could replace the current rules based on market prices. Parties like the Study Group on Drug Pricing and Distribution…

By Eric Persoff

Healthcare in the US is a highly political topic, with one end of the political spectrum arguing for broader government-sponsored access and the other advocating for more of a free-market approach. While the US market has typically been the primary…

By Reiji Anasako

The average ratio of females in managerial posts at Japanese drug makers has finally reached a double-digit number, at 10.0%, a Jiho survey found. However, this is still well below a near-25% ratio logged by foreign players operating in the…

Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…

Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…

A total of 15 new drugs (APIs) joined the NHI price list in 2021 with peak sales forecasts topping at 10 billion yen, many of them in the area of orphan diseases and with few mega launches, according to a…